Sendai Isawa Family Katsuyama Sake Brewery: SAMURAI SAKE: Reviving a 300-Year-Old Recipe
16.1.2025 06:00:00 CET | Business Wire | Press release
“RYOAN LEGEND 2012 Junmai Daiginjo-DOUBLE UMAMI FINISH - Umami Grand Cru” New Release
Sendai Isawa Family Katsuyama Sake Brewery Co., Ltd.:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250109261916/en/
Presented in a handcrafted Sendai Tansu (Photo: Business Wire)
A Legacy of Supporting Sendai's Samurai Warlord, Date Masamune
Sendai Isawa Family Katsuyama Sake Brewery Co., Ltd., which has a history of over 330 years as the official sake brewer for the Sendai Domain founded by the feudal lord Date Masamune, released RYOAN LEGEND 2012 Junmai Daiginjo-DOUBLE UMAMI FINISH - Umami Grand Cruon December, 2024.
This sake, crafted by unraveling a recipe from 300 years ago, achieves a quality that extracts "twice the umami components of rice" through Katsuyama Brewery's unique centrifugal pressing method. Then, through 12 years of ice aging at minus 5 degrees Celsius, this sake has reached a level of maturity brought about by time.
Shaped by Date Masamune's legacy as a samurai leader and cultural patron, Sendai embodies his vision through international exchange and crafts like Sendai Tansu. Katsuyama Sake Brewery, the Date family's official brewery for over 300 years, honors this heritage while crafting globally renowned sake.
Winner of Prestigious Sake Competitions Worldwide!
Katsuyama Sake Brewery has earned numerous accolades. Junmai Ginjo "Ken" topped the SAKE COMPETITION in 2015 and 2016 and was Champion Sake at the 2019 London IWC. That year, Junmai Daiginjo "Den" won the President Sake title at France's KURA MASTER. Flagship Junmai Daiginjo "Akatsuki" scored 95 points from Robert Parker's Wine Advocate in 2016, ranked first among 800 new sakes, and placed second in the 2024 SAKE COMPETITION Super Premium category.
An Uniquely Exceptional Sake, Reviving a 300-Year-Old Recipe
The theme "Ryoan" honors Heizaemon Isawa, the sixth-generation owner of Katsuyama Sake Brewery, who played a key role in Sendai's growth. His restoration of Zuihō-ji, the Date family's ancestral temple, preserved traditional culture. Inspired by the legacies of Masamune and Heizaemon, RYOAN LEGEND 2012 Junmai Daiginjo embodies Sendai's history, Samurai’s pride, and innovation.
Inspired by Edo-period (1603-1868) sake recipes, this sake combines tradition and innovation. Using historical methods, it amplifies umami, unlocking rice's potential for a rich, smooth finish. Made from 2012 Yamada Nishiki Special A rice, grown near Mount Izumigatake with silica-rich water, it reflects Katsuyama’s unique terroir. With centrifugal extraction and 12 years of cold aging, it achieves a perfect balance of depth, umami, and crispness.
Presented in a handcrafted Sendai Tansu, this limited release of 50 sets offers an unparalleled experience of premium rice’s sake.
RYOAN LEGEND 2012 Junmai Daiginjo-DOUBLE UMAMI FINISH - Umami Grand Cru |
Ingredients: Rice (domestic), Rice Koji (domestic rice) |
Polishing Ratio: 35% |
Rice Variety: 100% Yamada Nishiki |
Alcohol Content: 16% |
Volume: 720ml |
Storage: Refrigerated (room temperature during transport is acceptable) |
Brewmaster: Mitsuaki Goto |
Recommended Serving Temperature: 8–14°C |
Price: ¥1,000,000 (excluding tax) |
Sales: Limited to 50 bottles |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109261916/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom